I'm feeling a lot more optimistic on the market now and believe the end of the pain is in sight.
And whilst it may still be a touch soon to go all in, I think it is well worth being prepared for action when the time comes.
Here are five top ASX shares for growth investors to consider buying before the market rebounds:
a2 Milk Company Ltd (ASX: A2M)
The first share to consider buying is this New Zealand-based fresh milk and infant formula company. It has been growing its earnings at an explosive rate over the last few years. I'm confident this strong form can continue for some time to come thanks to the increasing demand for its infant formula products in the massive China market.
Altium Limited (ASX: ALU)
Altium is a printed circuit board (PCB) design software provider. I believe it is a great long term option due to the Internet of Things boom. Global technology spending on the Internet of Things is expected to grow at a rapid rate over the next decade. This should lead to increasing demand for its award-winning software.
CSL Limited (ASX: CSL)
Another top share to consider buying before the market rebounds is CSL. Due to the quality and strength of the biotherapeutics company's CSL Behring and Seqirus businesses, I believe it is well-positioned for solid long term growth. Especially given the increasing demand for existing therapies, its growing plasma collection network, and its pipeline of potentially lucrative products.
ResMed Inc. (ASX: RMD)
ResMed is a medical device company focused on the sleep treatment market. Thanks to its industry-leading products and its massive market opportunity, I believe it can deliver further strong earnings growth over the next decade. In respect to its market opportunity, management estimates that there are 1 billion people impacted by sleep apnoea worldwide. However, only ~20% of these sufferers had been diagnosed at the end of FY 2019.
SEEK Limited (ASX: SEK)
This job listings company could be a great share to own over the next decade thanks to its investments in growth opportunities. These investments are expected to play a key role in the company achieving its aspirational revenue target of $5 billion by FY 2025. This will be a materially lift on the revenue of $1,537.3 million it recorded in FY 2019.
